Trump announces trade deal with EU following months of negotiations
Investing.com -- GlaxoSmithKline plc (NYSE:GSK) shares gained 2.2% after the pharmaceutical giant reported first-quarter earnings and revenue that exceeded analyst estimates, driven by strong growth in its Specialty Medicines segment. The company also reaffirmed its full-year 2025 guidance.
GSK posted adjusted earnings per share of $1.20, surpassing the consensus estimate of $1.02. Revenue for the quarter came in at $10.06 billion, beating expectations of $9.48 billion and representing a 4% year-over-year increase at constant exchange rates.
The company’s Specialty Medicines division was the standout performer, with sales growing 17% to £2.9 billion. Within this segment, Respiratory, Immunology and Inflammation products saw a 28% increase, while Oncology sales surged 53%. HIV sales also contributed positively, rising 7% to £1.7 billion.
Vaccines sales declined 6% to £2.1 billion, with Shingrix sales down 7%. However, Meningitis vaccines showed strong growth of 20%. General Medicines sales remained stable at £2.5 billion, with Trelegy sales up 15%.
"GSK continues to make strong progress, demonstrating the quality, strength and resilience of our portfolio," said CEO Emma Walmsley. "Specialty Medicines, our largest business, delivered strong sales contributions in the quarter and R&D progress continued, with two of the five FDA product approvals expected this year now secured."
The company reaffirmed its full-year 2025 guidance, expecting turnover growth of 3% to 5%, core operating profit growth of 6% to 8%, and core EPS growth of 6% to 8%, all at constant exchange rates.
GSK also declared a quarterly dividend of 16p per share and announced it had bought back £273 million of shares as part of its £2 billion share buyback program initiated in Q1 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.